Alivus Life Sciences Limited

Alivus Life Sciences Limited (ALIVUS) is a small-cap Healthcare company valued at ₹16,073 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Alivus Life Sciences Limited last traded at ₹1,308.4, down 2.49% on the day.

Recent developments

On 2026-09-01, the company announced a dividend of ₹5.00 per share, effective from that date. The foreign institutional holding increased by 0.25 percentage points in the latest quarter, while domestic institutional holding decreased by 0.10 percentage points.

Financial performance

The company's business has improved, with annual revenue rising 6.9% and net profit growing 16.1% year-over-year. The latest quarter saw revenue increase 6.4% compared to the same quarter a year earlier, while net profit surged 31.2%, indicating stronger profitability in recent months.

Valuation multiples

The stock trades at 28.4 times earnings, broadly in line with the Healthcare median of 32.0, 5.13 times book value. It yields 0.4%.

Things to watch

The stock is 8.0% below its 52-week high, which may indicate a pullback from recent peak levels. The company's net profit margin, while up, remains at 22.1%, which is relatively high for the sector. Promoter holding remains at 74.87%, but there is no recent change in promoter ownership.

Where it stands

The company has shown consistent revenue and profit growth over the past five years, with recent quarters reflecting stronger performance. The most significant movement was in the latest quarter, where net profit rose sharply. The stock is currently trading below its 52-week high.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.